Reata rout leaves next project in doubt
Bardoxolone looks dead after yesterday’s adcom vote, but what about omaveloxolone?
Vertex finally catches a break
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.
ESC 2021 – finerenone’s song gets a little sweeter
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Dicerna can’t catch up with Alnylam
Phyox2 data back Dicerna’s nedosiran in just one type of primary hyperoxaluria, where Alnylam already has an 18-month head start.
